Method and kit for measuring the effectiveness of bronchodilators

• US 4,852,582 A
• Filed: 09/11/1987
• Issued: 08/01/1989
• Est. Priority Date: 09/11/1987
• Status: Expired due to Fees

• Current Assignee: Pell, Donald M.
• Original Assignee: Pell, Donald M.
• Inventors: Pell, Donald M.
• Primary Examiner(s): Cohen, Lee S.
• Assistant Examiner(s): Hanley, John C.
• Application Number:
  US07/095,232
• Time in Patent Office: 690 Days
• Field of Search: 128/716, 128/725, 128/726, 128/727, 128/728, 128/729
• US Class Current: 600/529
• CPC Class Codes: A61B 5/0871 Peak expiratory flowmeters

Abstract

A method and kit for measuring the effectiveness of various bronchodilators on an individual patient are disclosed. For example, the kit includes a plurality of bronchodilator test solutions and a nebulizer for providing a dose of each solution for introduction into a patient'"'"'s lungs. A spirometer or other type of flowmeter is also provided for measuring the flow characteristics of a patient'"'"'s forced expiratory flow before and after inspiration of each of the bronchodilator solutions. A test panel is also provided for recording and comparing the patient'"'"'s flow data before and after inspiration of each of the test solutions. And, in a preferred embodiment of the invention, the patient'"'"'s lungs are rechallenged to verify the best treatment for the patient. And, a second embodiment includes instructions and a peak flow meter in place of a spirometer, so that the tests may be self-administered in a patient'"'"'s home.

Claims

1. A kit for measuring the effectiveness of various bronchodilators on an individual patient comprising a plurality of bronchodilator test solutions and a nebulizer means for providing a measured dose of each test solution for introduction into a patient'"'"'s lungs, means for measuring a patient'"'"'s forced expiratory flow data and a test panel means for recording the flow data before and after inspiration of each of the plurality of bronchodilator test solutions and for visual comparison of the quantitative results for determining the effectiveness of the bronchodilators.

2. A kit for measuring the effectiveness of bronchodilators in an individual patient according to claim 1 in which the bronchodilator test solutions include saline solutions of metaproterenol with atropine sulfate, isoetherine with atropine sulfate, terbutaline with atropine sulfate and albuterol with atropine sulfate, and in which the means for measuring the patient'"'"'s forced expiratory flow data is a peak flowmeter and in which the test panel means includes designated spaces for recording peak expiratory flow and the kit includes a set of instructions for self administration of the test.

3. A kit for measuring the effectiveness of bronchodilators in an individual patient according to claim 2 in which there is a sufficient amount of each of said test solutions for conducting at least four tests and wherein the test panel means includes designated spaces for recording the results of the four tests.

4. A kit for measuring the effectiveness of bronchodilators in an individual patient according to claim 1 in which said plurality of bronchodilator test solutions include eight saline solutions of metaproterenol, isoetherine, terbutaline and albuterol with and without 0.8% mg of atropine sulfate and in which the means for measuring the patient'"'"'s forced expiratory flow data is a spirometer and the test panel includes designated spaces for recording a patient'"'"'s vital capacity and forced expiratory volume during the first second of expiration before and after each test of a bronchodilator solution.

5. A kit for measuring the effectiveness of bronchodilators in an individual patient according to claim 4 in which there is a sufficient amount of each of said test solutions for conducting two tests and wherein the test panel means includes designated spaces for recording the results of both tests.

6. A kit for measuring the effectiveness of bronchodilators in an individual patient according to claim 4 in which the measured does are as follows:

0.3 ml. of a 5% saline solution of metaproterenol, 0.5% ml of a 0.125% saline solution of isoetherine, 1.0 ml of a 1% saline solution of terbutaline, 0.5 ml of a 5% saline solution of albuterol and each of the aforementioned doses mixed with 0.8 ml of a saline solution of atropine sulfate.

7. A method for measuring the effectiveness of bronchodilators on an individual patient comprising the steps of:

a. providing a plurality of bronchodilator test solutions;

b. measuring and recording the forced expiratory flow of the patient after at least 4 hours following after any use of a bronchodilator;

c. nebulizing a first one of the test solutions;

d. introducing the nebulized solution into the patient'"'"'s lungs and maintaining the nebulized solution therein for at least several seconds before expiration thereof;

e. waiting for a period of at least about 8 minutes;

f. measuring and recording the forced expiratory flow of the patient during the first second of forced expiration;

g. waiting for a period of at least about four hours without additional inhalation of a bronchodilator; and

h. repeating steps a through g for each of the remaining bronchodilators until step f has been completed for the last test solution; and

i. comparing any improvement in post treatment flow over the pretreatment flow for each of the bronchodilator test solutions and determining the most effective treatment for the patient.

8. A method for measuring the effectiveness of bronchodilators in an individual patient according to claim 7 wherein at least one of the plurality of bronchodilators includes an anticholinergic, and wherein steps b-f include the steps of measuring and recording the vital capacity and forced expiratory volume in the first second of expiration.

9. A method for measuring the effectiveness of bronchodilators in an individual patient according to claim 8 wherein multiple tests are performed with each of the bronchodilator solutions and in which peak expiratory flow is measured and recorded before and after each of the tests.

10. A method for measuring the effectiveness of bronchodilators in an individual patient according to claim 7 which includes the step of displaying the forced expiratory flow during the first second of expiration and further including the step of rechallenging the lungs by retesting the two bronchodilator test solutions which provided the maximum improvements during the first series of tests to thereby verify which is the best treatment for the patient.